| Gene | Score gda | Association Type | Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
0.080 | Biomarker | phenotype | BEFREE | The cross-talk between NGF and insulin pathways downstream the insulin receptor suggests novel potential therapeutic targets to slow cognitive decline in AD and diabetes-related brain insulin resistance. | 29736736 | 2019 | ||||
|
0.080 | Biomarker | phenotype | BEFREE | The NGF pathway may also have potential as a biomarker of cognitive decline in AD, as its changes can predict future cognitive decline in patients with Down syndrome as they develop preclinical Alzheimer's pathology. | 30809111 | 2019 | ||||
|
0.080 | Biomarker | phenotype | BEFREE | To determine whether stereotactically guided intracerebral injections of adeno-associated viral vector (serotype 2)-nerve growth factor (AAV2-NGF) are well tolerated and exhibit preliminary evidence of impact on cognitive decline in mild to moderate AD-associated dementia. | 29582053 | 2018 | ||||
|
0.080 | Biomarker | phenotype | BEFREE | According to much research, neurodegeneration and cognitive decline in Alzheimer disease (AD) are correlated with alternations of neurotrophic factors such as nerve growth factor, brain-derived neurotrophic factor, and glial cell-derived neurotrophic factor. | 29114922 | 2018 | ||||
|
0.080 | Biomarker | phenotype | BEFREE | Dysfunction of nerve growth factor (NGF) and its high-affinity Tropomyosin receptor kinase A (TrkA) receptor has been suggested to contribute to the selective degeneration of basal forebrain cholinergic neurons (BFCN) associated with the progressive cognitive decline in Alzheimer's disease (AD). | 28632177 | 2017 | ||||
|
0.080 | Biomarker | phenotype | BEFREE | To test whether encapsulation of this cell line provides a relevant dose escalation step in delivering NGF for treatment of the cognitive decline in AD patients, we have validated the bioactivity of devices with NGC0211 and NGC-0295 cells in normal rat striatum as well as in the quinolinic acid striatal lesion model. | 22113314 | 2012 | ||||
|
0.080 | Biomarker | phenotype | BEFREE | The therapeutic potential of using human NGF to provide a long-lasting cholinergic trophic support, thereby preventing or slowing cognitive decline in AD patients, has therefore a strong rationale. | 19355851 | 2009 | ||||
|
0.080 | Biomarker | phenotype | BEFREE | A NGF gene therapy trial reduced cognitive decline and stimulated cholinergic fiber growth in humans with mild AD. | 18986241 | 2008 |